EU/3/17/1855
Table of contents
About
On 20 March 2017, orphan designation (EU/3/17/1855) was granted by the European Commission to GW Research Ltd, United Kingdom, for cannabidiol for the treatment of Lennox-Gastaut syndrome.
The sponsorship was transferred to GW Pharma (International) B.V., the Netherlands, in April 2019.
Cannabidiol for treatment of Dravet syndrome and treatment of Lennox-Gastaut has been authorised in the EU as Epidyolex since 19 September 2019.
Key facts
Active substance |
Cannabidiol
|
Disease / condition |
Treatment of Lennox-Gastaut syndrome
|
Date of first decision |
20/03/2017
|
Outcome |
Positive
|
EU designation number |
EU/3/17/1855
|
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Epidyolex at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the
orphan medicine assessment report
.
Sponsor's contact details
GW Pharma (International) B.V.
Databankweg 26
Amersfoort
Utrecht
3821 AL
Netherlands
Tel: +31 (0) 33 798 1015
E-mail: gwreg@gwpharm.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.